Informatie:
Fout:
ID
30801
Beschrijving
Study part: Treatment confirmation. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.
Trefwoorden
Versies (1)
- 20-06-18 20-06-18 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
20 juni 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Treatment confirmation Pazopanib Macular Degeneration MD1103367
Treatment confirmation
- StudyEvent: ODM
Similar models
Treatment confirmation
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
TREATMENT CONFIRMATION (Trt Cont)
C0087111 (UMLS CUI-1)
C0750484 (UMLS CUI-2)
C0750484 (UMLS CUI-2)
Item
Did the subject receive the correct treatment (e.g., treatment which the subject was assigned to) during this dosing interval?
text
C1522541 (UMLS CUI [1])
Code List
Did the subject receive the correct treatment (e.g., treatment which the subject was assigned to) during this dosing interval?
CL Item
Yes (Y)
CL Item
No (N)
reason therapy assigned
Item
When no, record reason
text
C0392360 (UMLS CUI [1,1])
C1522541 (UMLS CUI [1,2])
C1522541 (UMLS CUI [1,2])